Study Reveals Metformin May Hinder Exercise Benefits for Diabetics

A recent study from Rutgers University indicates that the widely prescribed diabetes medication metformin may impede the health benefits gained from exercise for individuals with type 2 diabetes. The findings suggest that this common treatment could undermine patients’ efforts to improve their cardiovascular health and overall fitness.

Researchers conducted a double-blind, placebo-controlled trial involving 72 adults at risk for metabolic syndrome. The study assessed how metformin affected vascular insulin sensitivity—an important factor in managing blood sugar and preventing cardiovascular disease—during exercise. Lead author Steven Malin, a professor in the Department of Kinesiology and Health, emphasized that while healthcare providers typically assume that exercise combined with medication leads to better health outcomes, the evidence indicates that metformin may lessen the benefits of physical activity.

Participants were divided into four groups: those engaging in high-intensity exercise with either metformin or a placebo, and those doing low-intensity exercise with the same conditions. Over a period of 16 weeks, the researchers monitored changes in blood vessel function, aerobic fitness, and body composition.

Results showed that individuals in the placebo groups—regardless of exercise intensity—experienced significant improvements in aerobic fitness. In contrast, those taking metformin did not exhibit any enhancement in fitness levels. Notably, participants on metformin also displayed no improvement in vascular insulin sensitivity, suggesting that exercise failed to produce the expected positive effects on their cardiovascular health.

Moreover, while there was a reduction in body fat across all groups except for those taking metformin, the high-intensity exercisers on the drug showed worsened inflammatory and fasting glucose levels. “Blood vessel function improved with exercise training, regardless of intensity,” Malin noted. “Metformin blunted that observation, suggesting one type of exercise intensity is not better either with the drug for blood vessel health.”

Since the introduction of metformin in 2006, healthcare providers have recommended a combination of medication and lifestyle changes, operating under the assumption that regular exercise would enhance the efficacy of diabetes treatments. With over 20 million Americans currently prescribed metformin, these findings raise significant concerns. Malin pointed out, “If you exercise and take metformin and your blood glucose does not go down, that’s a problem.” He added that the lack of fitness improvement among these individuals poses potential long-term health risks.

While the exact mechanism by which metformin disrupts the benefits of exercise remains unclear, the researchers speculate that it may relate to the drug’s influence on cellular mitochondria. Metformin appears to suppress mitochondrial function, which is crucial for energy production and optimal exercise outcomes. This suppression could counteract the anticipated benefits of exercise, such as enhanced aerobic fitness and improved cardiovascular health.

The implications of this study are profound, yet the authors caution against discontinuing metformin or exercise. Instead, they advocate for closer monitoring of patients who are not experiencing the expected benefits from physical activity. Malin emphasized the need for further research to determine how to best integrate exercise recommendations with metformin therapy.

The findings were published in the Journal of Clinical Endocrinology & Metabolism, highlighting the necessity for healthcare professionals to re-evaluate treatment guidelines for diabetes management. As this research unfolds, it will be essential to explore alternative strategies to ensure that individuals with diabetes can effectively benefit from exercise without the limitations imposed by their medication.